The Zhitong Finance App learned that Zhongsheng Pharmaceutical (01177) is now up nearly 6%. As of press release, it has risen 6.19% to HK$3.09, with a turnover of HK$159 million.

According to the news, China Biopharmaceutical announced that “Benmelstobart (TQB2450)” (trade name: Andevil), a Class 1 innovative drug independently developed by the Group, has obtained marketing approval from the China National Drug Administration. It is used in combination with anlotinib hydrochloride capsules, carboplatin, and etopogan for first-line treatment of patients with extensive small cell lung cancer (ES-SCLC). According to reports, this is the first indication approved for bemosubizumab injections in China.

In addition, China Biopharmaceutical previously announced that the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor),” “abergastine α (third-generation long-acting G-CSF),” “piamprizumab (anti-PD-1),” and the new drug projects “FS222 (PD-L1/CD137 double antibody)” and “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728 (IAP antagonist)”, “TQB2930” (HER2 double antibody)” etc. will be The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting announced 52 recent research results, covering clinical research and basic research on various tumors such as bone and soft tissue sarcoma, lung cancer, head and neck tumors, digestive system tumors, gynecological tumors, breast cancer, and malignant tumors.